Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07444710CT.gov Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07003295CT.gov Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy | — | Recruiting | — | — | — |
NCT07548255CT.gov The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL | — | Not Yet Recruiting | — | — | — |
NCT07453095CT.gov Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy | — | Not Yet Recruiting | — | — | — |
NCT07261163CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT07460362CT.gov Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06357676CT.gov Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | — | Recruiting | — | — | — |
NCT06558604CT.gov Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma | — | Recruiting | — | — | — |
NCT06054776CT.gov Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06656221CT.gov A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
Show 20 more trialsShow fewer
NCT06504199CT.gov Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06252675CT.gov Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT06427213CT.gov This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT06324994CT.gov Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma. | — | Not Yet Recruiting | — | — | — |
NCT06192888CT.gov A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05833763CT.gov A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure. | — | Recruiting | — | — | — |
NCT05861050CT.gov Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | — | Recruiting | — | — | — |
NCT04599634CT.gov Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies | — | Completed | — | — | — |
NCT04883437CT.gov Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas | — | Recruiting | — | — | — |
NCT04855695CT.gov Avo In R/R And Previously Untreated MCL | — | Recruiting | — | — | — |
NCT04703686CT.gov Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy | — | Completed | — | — | — |
NCT04578600CT.gov CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma | — | Completed | — | — | — |
NCT03863184CT.gov Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL | — | Active Not Recruiting | — | — | — |
NCT03872180CT.gov Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03229382CT.gov Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse | — | Terminated | — | — | — |
NCT03311126CT.gov Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma | — | Terminated | — | — | — |
NCT03010358CT.gov Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02896582CT.gov Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance | — | Completed | — | — | — |
NCT02736617CT.gov Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | — | Completed | — | — | — |
NCT02558816CT.gov A Trial of Obinutuzumab,GDC-0199 Plus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Mantle Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Obinutuzumab (this asset) | National Cancer Institute (NCI) | P2 | BB · 64 |
| Etoposide | Ruijin Hospital | P4 | BBB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P4 | BBB |
| Busulfanum | City of Hope Medical Center | P2 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Irinotecan | University of Michigan Rogel Cancer Center | P2 | BBB |
| Vincristine Sulfate | M.D. Anderson Cancer Center | P2 | BBB |
| Cediranib | City of Hope Medical Center | P2 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P2 | BB |
+42 more in the Mantle Cell Lymphoma cohort
Other indications for Obinutuzumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Richter Transformation | — | P2 | BB · 71 |
| B-Cell Chronic Lymphocytic Leukemia | — | P3 | BB · 71 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Obinutuzumab in Mantle Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/obinutuzumab-mantle-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →